December 2004 Cover
|
 |
Better Than Combivir?
Gilead Sciences' once-daily combination antiretroviral drug Truvada is more effective at slowing the progression of HIV than GlaxoSmithKline's twice-daily antiretroviral Combivir, according to preliminary data.
The trial included 487 HIV-positive people who had never taken antiretrovirals. One group took Truvada-- a combination of Viread and Emtriva-- as well as Bristol Myers Squibb's Sustiva, generically known as efavirenz; a second group took Combivir-- which
contains zidovudine and lamivudine-- and Sustiva. Truvada succeeded in reducing HIV viral loads to fewer than 400 copies per milliliter of blood after 24 weeks in 88% of individuals on the drug, compared with 80% among the people who took Combivir. Three percent of the people
who took Truvada discontinued the drug because of adverse reactions, compared with 9% of people who took Combivir.
Editor's Note: from TheBodyPro.com
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
